Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.

Alzheimer's research & therapy

Sha SJ, Ghosh PM, Lee SE, Corbetta-Rastelli C, Jagust WJ, Kornak J, Rankin KP, Grinberg LT, Vinters HV, Mendez MF, Dickson DW, Seeley WW, Gorno-Tempini M, Kramer J, Miller BL, Boxer AL, Rabinovici GD.
PMID: 25733984
Alzheimers Res Ther. 2015 Mar 02;7(1):8. doi: 10.1186/s13195-014-0093-y. eCollection 2015.

INTRODUCTION: Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer's disease (AD) pathology versus those with underlying frontotemporal lobar degeneration (FTLD). The value of these...

Cite
Sha SJ, Ghosh PM, Lee SE, et al. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther. 2015;7(1):8doi: 10.1186/s13195-014-0093-y.
Sha, S. J., Ghosh, P. M., Lee, S. E., Corbetta-Rastelli, C., Jagust, W. J., Kornak, J., Rankin, K. P., Grinberg, L. T., Vinters, H. V., Mendez, M. F., Dickson, D. W., Seeley, W. W., Gorno-Tempini, M., Kramer, J., Miller, B. L., Boxer, A. L., & Rabinovici, G. D. (2015). Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimer's research & therapy, 7(1), 8. https://doi.org/10.1186/s13195-014-0093-y
Sha, Sharon J, et al. "Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography." Alzheimer's research & therapy vol. 7,1 (2015): 8. doi: https://doi.org/10.1186/s13195-014-0093-y
Sha SJ, Ghosh PM, Lee SE, Corbetta-Rastelli C, Jagust WJ, Kornak J, Rankin KP, Grinberg LT, Vinters HV, Mendez MF, Dickson DW, Seeley WW, Gorno-Tempini M, Kramer J, Miller BL, Boxer AL, Rabinovici GD. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther. 2015 Mar 02;7(1):8. doi: 10.1186/s13195-014-0093-y. eCollection 2015. PMID: 25733984; PMCID: PMC4346122.
Copy Download .nbib Format: NLM
Treatment of frontotemporal dementia.

Current treatment options in neurology

Tsai RM, Boxer AL.
PMID: 25238733
Curr Treat Options Neurol. 2014 Nov;16(11):319. doi: 10.1007/s11940-014-0319-0.

OPINION STATEMENT: Frontotemporal dementia (FTD) encompasses a spectrum of neurodegenerative diseases with heterogeneous clinical presentations and two predominant types of underlying neuropathology. FTD typically comprises three distinct clinical syndromes: behavioral variant frontotemporal dementia (bvFTD), semantic variant primary progressive aphasia...

Cite
Tsai RM, Boxer AL. Treatment of frontotemporal dementia. Curr Treat Options Neurol. 2014;16(11):319doi: 10.1007/s11940-014-0319-0.
Tsai, R. M., & Boxer, A. L. (2014). Treatment of frontotemporal dementia. Current treatment options in neurology, 16(11), 319. https://doi.org/10.1007/s11940-014-0319-0
Tsai, Richard M, and Boxer, Adam L. "Treatment of frontotemporal dementia." Current treatment options in neurology vol. 16,11 (2014): 319. doi: https://doi.org/10.1007/s11940-014-0319-0
Tsai RM, Boxer AL. Treatment of frontotemporal dementia. Curr Treat Options Neurol. 2014 Nov;16(11):319. doi: 10.1007/s11940-014-0319-0. PMID: 25238733; PMCID: PMC4920050.
Copy Download .nbib Format: NLM
Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory.

Annals of clinical and translational neurology

Ljubenkov PA, Staffaroni AM, Rojas JC, Allen IE, Wang P, Heuer H, Karydas A, Kornak J, Cobigo Y, Seeley WW, Grinberg LT, Spina S, Fagan AM, Jerome G, Knopman D, Boeve BF, Dickerson BC, Kramer J, Miller B, Boxer AL, Rosen HJ.
PMID: 30349860
Ann Clin Transl Neurol. 2018 Sep 20;5(10):1250-1263. doi: 10.1002/acn3.643. eCollection 2018 Oct.

OBJECTIVE: The prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tauMETHODS: We compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotemporal dementia, 24 with semantic variant primary progressive aphasia, and 26 with nonfluent...

Cite
Ljubenkov PA, Staffaroni AM, Rojas JC, et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol. 2018;5(10):1250-1263doi: 10.1002/acn3.643.
Ljubenkov, P. A., Staffaroni, A. M., Rojas, J. C., Allen, I. E., Wang, P., Heuer, H., Karydas, A., Kornak, J., Cobigo, Y., Seeley, W. W., Grinberg, L. T., Spina, S., Fagan, A. M., Jerome, G., Knopman, D., Boeve, B. F., Dickerson, B. C., Kramer, J., Miller, B., Boxer, A. L., & Rosen, H. J. (2018). Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Annals of clinical and translational neurology, 5(10), 1250-1263. https://doi.org/10.1002/acn3.643
Ljubenkov, Peter A, et al. "Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory." Annals of clinical and translational neurology vol. 5,10 (2018): 1250-1263. doi: https://doi.org/10.1002/acn3.643
Ljubenkov PA, Staffaroni AM, Rojas JC, Allen IE, Wang P, Heuer H, Karydas A, Kornak J, Cobigo Y, Seeley WW, Grinberg LT, Spina S, Fagan AM, Jerome G, Knopman D, Boeve BF, Dickerson BC, Kramer J, Miller B, Boxer AL, Rosen HJ. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol. 2018 Sep 20;5(10):1250-1263. doi: 10.1002/acn3.643. eCollection 2018 Oct. PMID: 30349860; PMCID: PMC6186942.
Copy Download .nbib Format: NLM
Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease.

JAMA neurology

Staffaroni AM, Kramer AO, Casey M, Kang H, Rojas JC, Orrú CD, Caughey B, Allen IE, Kramer JH, Rosen HJ, Blennow K, Zetterberg H, Geschwind MD.
PMID: 31058916
JAMA Neurol. 2019 Aug 01;76(8):969-977. doi: 10.1001/jamaneurol.2019.1071.

IMPORTANCE: Fluid biomarkers that can predict survival time in sporadic Creutzfeldt-Jakob disease (sCJD) will be critical for clinical care and for treatment trials.OBJECTIVE: To assess whether plasma and cerebrospinal fluid (CSF) biomarkers are associated with survival time in patients...

Cite
Staffaroni AM, Kramer AO, Casey M, et al. Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurol. 2019;76(8):969-977doi: 10.1001/jamaneurol.2019.1071.
Staffaroni, A. M., Kramer, A. O., Casey, M., Kang, H., Rojas, J. C., Orrú, C. D., Caughey, B., Allen, I. E., Kramer, J. H., Rosen, H. J., Blennow, K., Zetterberg, H., & Geschwind, M. D. (2019). Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. JAMA neurology, 76(8), 969-977. https://doi.org/10.1001/jamaneurol.2019.1071
Staffaroni, Adam M, et al. "Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease." JAMA neurology vol. 76,8 (2019): 969-977. doi: https://doi.org/10.1001/jamaneurol.2019.1071
Staffaroni AM, Kramer AO, Casey M, Kang H, Rojas JC, Orrú CD, Caughey B, Allen IE, Kramer JH, Rosen HJ, Blennow K, Zetterberg H, Geschwind MD. Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurol. 2019 Aug 01;76(8):969-977. doi: 10.1001/jamaneurol.2019.1071. PMID: 31058916; PMCID: PMC6503575.
Copy Download .nbib Format: NLM
Plasma neurofilament light chain predicts progression in progressive supranuclear palsy.

Annals of clinical and translational neurology

Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, Kramer JH, Rosen H, Miller BL, Zetterberg H, Boxer AL.
PMID: 27042681
Ann Clin Transl Neurol. 2016 Feb 01;3(3):216-25. doi: 10.1002/acn3.290. eCollection 2016 Mar.

OBJECTIVE: Blood-based biomarkers for neurodegenerative conditions could improve diagnosis and treatment development. Neurofilament light chain (NfL), a marker of axonal injury, is elevated in cerebrospinal fluid (CSF) of patients with progressive supranuclear palsy (PSP). The goal of this study...

Cite
Rojas JC, Karydas A, Bang J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3(3):216-25doi: 10.1002/acn3.290.
Rojas, J. C., Karydas, A., Bang, J., Tsai, R. M., Blennow, K., Liman, V., Kramer, J. H., Rosen, H., Miller, B. L., Zetterberg, H., & Boxer, A. L. (2016). Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Annals of clinical and translational neurology, 3(3), 216-25. https://doi.org/10.1002/acn3.290
Rojas, Julio C, et al. "Plasma neurofilament light chain predicts progression in progressive supranuclear palsy." Annals of clinical and translational neurology vol. 3,3 (2016): 216-25. doi: https://doi.org/10.1002/acn3.290
Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, Kramer JH, Rosen H, Miller BL, Zetterberg H, Boxer AL. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016 Feb 01;3(3):216-25. doi: 10.1002/acn3.290. eCollection 2016 Mar. PMID: 27042681; PMCID: PMC4774256.
Copy Download .nbib Format: NLM
Redefining Human Vitamin D Sufficiency: Back to the Basics.

Bone research

Adams JS, Ramin J, Rafison B, Windon C, Windon A, Liu PT.
PMID: 25285234
Bone Res. 2013;1(1):2-10. doi: 10.4248/BR201301002.

No abstract available.

Cite
Adams JS, Ramin J, Rafison B, et al. Redefining Human Vitamin D Sufficiency: Back to the Basics. Bone Res. 2013;1(1):2-10doi: 10.4248/BR201301002.
Adams, J. S., Ramin, J., Rafison, B., Windon, C., Windon, A., & Liu, P. T. (2013). Redefining Human Vitamin D Sufficiency: Back to the Basics. Bone research, 1(1), 2-10. https://doi.org/10.4248/BR201301002
Adams, John S, et al. "Redefining Human Vitamin D Sufficiency: Back to the Basics." Bone research vol. 1,1 (2013): 2-10. doi: https://doi.org/10.4248/BR201301002
Adams JS, Ramin J, Rafison B, Windon C, Windon A, Liu PT. Redefining Human Vitamin D Sufficiency: Back to the Basics. Bone Res. 2013;1(1):2-10. doi: 10.4248/BR201301002. PMID: 25285234; PMCID: PMC4180627.
Copy Download .nbib Format: NLM
Thorough work-up and new diagnostic criteria needed for CJD.

Nature reviews. Neurology

Perry DC, Geschwind MD.
PMID: 21892213
Nat Rev Neurol. 2011 Sep 05;7(9):479-80. doi: 10.1038/nrneurol.2011.118.

No abstract available.

Cite
Perry DC, Geschwind MD. Thorough work-up and new diagnostic criteria needed for CJD. Nat Rev Neurol. 2011;7(9):479-80doi: 10.1038/nrneurol.2011.118.
Perry, D. C., & Geschwind, M. D. (2011). Thorough work-up and new diagnostic criteria needed for CJD. Nature reviews. Neurology, 7(9), 479-80. https://doi.org/10.1038/nrneurol.2011.118
Perry, David C, and Geschwind, Michael D. "Thorough work-up and new diagnostic criteria needed for CJD." Nature reviews. Neurology vol. 7,9 (2011): 479-80. doi: https://doi.org/10.1038/nrneurol.2011.118
Perry DC, Geschwind MD. Thorough work-up and new diagnostic criteria needed for CJD. Nat Rev Neurol. 2011 Sep 05;7(9):479-80. doi: 10.1038/nrneurol.2011.118. PMID: 21892213; PMCID: PMC4134013.
Copy Download .nbib Format: NLM
Preclinical translation of exosomes derived from mesenchymal stem/stromal cells.

Stem cells (Dayton, Ohio)

Elahi FM, Farwell DG, Nolta JA, Anderson JD.
PMID: 31381842
Stem Cells. 2020 Jan;38(1):15-21. doi: 10.1002/stem.3061. Epub 2019 Oct 01.

Exosomes are nanovesicles secreted by virtually all cells. Exosomes mediate the horizontal transfer of various macromolecules previously believed to be cell-autonomous in nature, including nonsecretory proteins, various classes of RNA, metabolites, and lipid membrane-associated factors. Exosomes derived from mesenchymal...

Cite
Elahi FM, Farwell DG, Nolta JA, et al. Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. Stem Cells. 2019;38(1):15-21doi: 10.1002/stem.3061.
Elahi, F. M., Farwell, D. G., Nolta, J. A., & Anderson, J. D. (2020). Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. Stem cells (Dayton, Ohio), 38(1), 15-21. https://doi.org/10.1002/stem.3061
Elahi, Fanny M, et al. "Preclinical translation of exosomes derived from mesenchymal stem/stromal cells." Stem cells (Dayton, Ohio) vol. 38,1 (2020): 15-21. doi: https://doi.org/10.1002/stem.3061
Elahi FM, Farwell DG, Nolta JA, Anderson JD. Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. Stem Cells. 2020 Jan;38(1):15-21. doi: 10.1002/stem.3061. Epub 2019 Oct 01. PMID: 31381842; PMCID: PMC7004029.
Copy Download .nbib Format: NLM
Peripheral Innate Immune Activation Correlates With Disease Severity in .

Frontiers in neurology

Ljubenkov PA, Miller Z, Mumford P, Zhang J, Allen IE, Mitic L, Staffaroni A, Heuer H, Rojas JC, Cobigo Y, Karydas A, Pearlman R, Miller B, Kramer JH, McGrath MS, Rosen HJ, Boxer AL.
PMID: 31620075
Front Neurol. 2019 Sep 18;10:1004. doi: 10.3389/fneur.2019.01004. eCollection 2019.

No abstract available.

Cite
Ljubenkov PA, Miller Z, Mumford P, et al. Peripheral Innate Immune Activation Correlates With Disease Severity in . Front Neurol. 2019;10:1004doi: 10.3389/fneur.2019.01004.
Ljubenkov, P. A., Miller, Z., Mumford, P., Zhang, J., Allen, I. E., Mitic, L., Staffaroni, A., Heuer, H., Rojas, J. C., Cobigo, Y., Karydas, A., Pearlman, R., Miller, B., Kramer, J. H., McGrath, M. S., Rosen, H. J., & Boxer, A. L. (2019). Peripheral Innate Immune Activation Correlates With Disease Severity in . Frontiers in neurology, 101004. https://doi.org/10.3389/fneur.2019.01004
Ljubenkov, Peter A, et al. "Peripheral Innate Immune Activation Correlates With Disease Severity in ." Frontiers in neurology vol. 10 (2019): 1004. doi: https://doi.org/10.3389/fneur.2019.01004
Ljubenkov PA, Miller Z, Mumford P, Zhang J, Allen IE, Mitic L, Staffaroni A, Heuer H, Rojas JC, Cobigo Y, Karydas A, Pearlman R, Miller B, Kramer JH, McGrath MS, Rosen HJ, Boxer AL. Peripheral Innate Immune Activation Correlates With Disease Severity in . Front Neurol. 2019 Sep 18;10:1004. doi: 10.3389/fneur.2019.01004. eCollection 2019. PMID: 31620075; PMCID: PMC6759464.
Copy Download .nbib Format: NLM
Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes.

Brain communications

Townley RA, Graff-Radford J, Mantyh WG, Botha H, Polsinelli AJ, Przybelski SA, Machulda MM, Makhlouf AT, Senjem ML, Murray ME, Reichard RR, Savica R, Boeve BF, Drubach DA, Josephs KA, Knopman DS, Lowe VJ, Jack CR, Petersen RC, Jones DT.
PMID: 32671341
Brain Commun. 2020;2(1):fcaa068. doi: 10.1093/braincomms/fcaa068. Epub 2020 May 27.

We report a group of patients presenting with a progressive dementia syndrome characterized by predominant dysfunction in core executive functions, relatively young age of onset and positive biomarkers for Alzheimer's pathophysiology. Atypical frontal, dysexecutive/behavioural variants and early-onset variants of...

Cite
Townley RA, Graff-Radford J, Mantyh WG, et al. Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. Brain Commun. 2020;2(1):fcaa068doi: 10.1093/braincomms/fcaa068.
Townley, R. A., Graff-Radford, J., Mantyh, W. G., Botha, H., Polsinelli, A. J., Przybelski, S. A., Machulda, M. M., Makhlouf, A. T., Senjem, M. L., Murray, M. E., Reichard, R. R., Savica, R., Boeve, B. F., Drubach, D. A., Josephs, K. A., Knopman, D. S., Lowe, V. J., Jack, C. R., Petersen, R. C., & Jones, D. T. (2020). Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. Brain communications, 2(1), fcaa068. https://doi.org/10.1093/braincomms/fcaa068
Townley, Ryan A, et al. "Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes." Brain communications vol. 2,1 (2020): fcaa068. doi: https://doi.org/10.1093/braincomms/fcaa068
Townley RA, Graff-Radford J, Mantyh WG, Botha H, Polsinelli AJ, Przybelski SA, Machulda MM, Makhlouf AT, Senjem ML, Murray ME, Reichard RR, Savica R, Boeve BF, Drubach DA, Josephs KA, Knopman DS, Lowe VJ, Jack CR, Petersen RC, Jones DT. Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. Brain Commun. 2020;2(1):fcaa068. doi: 10.1093/braincomms/fcaa068. Epub 2020 May 27. PMID: 32671341; PMCID: PMC7325839.
Copy Download .nbib Format: NLM
Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.

Acta neuropathologica

Saijo E, Metrick MA, Koga S, Parchi P, Litvan I, Spina S, Boxer A, Rojas JC, Galasko D, Kraus A, Rossi M, Newell K, Zanusso G, Grinberg LT, Seeley WW, Ghetti B, Dickson DW, Caughey B.
PMID: 31748840
Acta Neuropathol. 2020 Jan;139(1):79-81. doi: 10.1007/s00401-019-02092-y.

The original version of this article unfortunately contained a mistake. The Panel A in the published figure 5 is incorrect. The corrected Figure 5 is placed in the following page.

Cite
Saijo E, Metrick MA, Koga S, et al. Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 2020;139(1):79-81doi: 10.1007/s00401-019-02092-y.
Saijo, E., Metrick, M. A., Koga, S., Parchi, P., Litvan, I., Spina, S., Boxer, A., Rojas, J. C., Galasko, D., Kraus, A., Rossi, M., Newell, K., Zanusso, G., Grinberg, L. T., Seeley, W. W., Ghetti, B., Dickson, D. W., & Caughey, B. (2020). Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta neuropathologica, 139(1), 79-81. https://doi.org/10.1007/s00401-019-02092-y
Saijo, Eri, et al. "Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration." Acta neuropathologica vol. 139,1 (2020): 79-81. doi: https://doi.org/10.1007/s00401-019-02092-y
Saijo E, Metrick MA, Koga S, Parchi P, Litvan I, Spina S, Boxer A, Rojas JC, Galasko D, Kraus A, Rossi M, Newell K, Zanusso G, Grinberg LT, Seeley WW, Ghetti B, Dickson DW, Caughey B. Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 2020 Jan;139(1):79-81. doi: 10.1007/s00401-019-02092-y. PMID: 31748840; PMCID: PMC7193369.
Copy Download .nbib Format: NLM
Spontaneous .

IDCases

Snyder A, Schmalzle SA.
PMID: 32405460
IDCases. 2020 May 05;20:e00785. doi: 10.1016/j.idcr.2020.e00785. eCollection 2020.

No abstract available.

Cite
Snyder A, Schmalzle SA. Spontaneous . IDCases. 2020;20:e00785doi: 10.1016/j.idcr.2020.e00785.
Snyder, A., & Schmalzle, S. A. (2020). Spontaneous . IDCases, 20e00785. https://doi.org/10.1016/j.idcr.2020.e00785
Snyder, A, and Schmalzle, S A. "Spontaneous ." IDCases vol. 20 (2020): e00785. doi: https://doi.org/10.1016/j.idcr.2020.e00785
Snyder A, Schmalzle SA. Spontaneous . IDCases. 2020 May 05;20:e00785. doi: 10.1016/j.idcr.2020.e00785. eCollection 2020. PMID: 32405460; PMCID: PMC7210579.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries